GLAXF
GSK plc
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Last price
25.50
▲ 0.15 (0.59%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
25.50
Prev close
25.35
Day high
24.29
Day low
24.29
Volume
150
Market cap
$102.14B
P/E (TTM)
15.94
52W range
18.99 – 31.48
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
69.96M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 11, 26 | Baxter (Lynn) |
BUY | 7 | $180 | Direct |
| Aug 11, 26 | Baxter (Lynn) |
— | 7 | — | Direct |
| Aug 11, 26 | Baxter (Lynn) |
BUY | 7 | $180 | Direct |
| Aug 11, 26 | Baxter (Lynn) |
— | 7 | — | Direct |
| Aug 11, 26 | Brown (Julie) |
BUY | 7 | $180 | Direct |
| Aug 11, 26 | Brown (Julie) |
— | 7 | — | Direct |
| Aug 11, 26 | Ford (J) |
BUY | 7 | $180 | Direct |
| Aug 11, 26 | Ford (J) |
— | 7 | — | Direct |
| Aug 11, 26 | Whyte (Victoria L) |
BUY | 6 | $155 | Direct |
| Aug 11, 26 | Whyte (Victoria L) |
— | 6 | — | Direct |
| Aug 11, 26 | Waterhouse (D) |
BUY | 7 | $180 | Direct |
| Aug 11, 26 | Waterhouse (D) |
— | 7 | — | Direct |
| Aug 11, 26 | Thomson (Phil C) |
BUY | 7 | $180 | Direct |
| Aug 11, 26 | Thomson (Phil C) |
— | 7 | — | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BlackRock Advisors (UK) Limited |
— | 229.13M | Annual Return |
Brown (Julie) |
— | 413.47K | Bought |
Dodge & Cox |
— | 88.82M | Decrease |
GSK Plc |
— | 270.88M | Holding |
GlaxoSmithKline Plc ESOP |
— | 62.88M | Annual Return |
Miels (Luke) |
— | 1.48M | Bought |
Redfern (David S) |
— | 1.10M | Bought |
Simard (Regis) |
— | 334.66K | Sold |
Thomson (Phil C) |
— | 529.08K | Bought |
Walmsley (Emma Natasha) |
— | 2.43M | Annual Return |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+0.31%
+1.7%
1M
+0.75%
-3.0%
3M
-1.92%
-5.0%
6M
-18.27%
-29.3%
YTD
+3.66%
-8.6%
1Y
+30.04%
+10.0%
3Y
+47.65%
-26.5%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$102.14B
Enterprise value$116.90B
Revenue (TTM)$33.20B
Gross profit$24.40B
EBITDA$10.82B
Net income$4.82B
EPS (TTM)$1.60
Free cash flow$3.48B
Total cash$3.11B
Total debt$18.29B
Book value / share$5.96
Shares outstanding4.01B
Float3.88B
Short % of float—
Dividend yield3.60%
Beta (5Y)0.30
Valuation & profitability ratios
Trailing P/E15.94
Forward P/E11.59
PEG ratio102.02
Price / sales—
Price / book4.28
EV / revenue3.52
EV / EBITDA10.81
Gross margin73.49%
Operating margin30.94%
Profit margin14.52%
Return on equity33.38%
Return on assets10.01%
Debt / equity106.50
Current ratio0.82
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $32.67B | $31.38B | $30.33B | $29.32B | +4.1% |
| Operating revenue | $32.67B | $31.38B | $30.33B | $29.32B | +4.1% |
| Cost of revenue | $9.02B | $9.05B | $8.56B | $9.55B | -0.3% |
| Gross profit | $23.65B | $22.33B | $21.76B | $19.77B | +5.9% |
| Research & development | $7.53B | $6.40B | $6.22B | $5.49B | +17.6% |
| Selling, general & admin | $9.09B | $11.02B | $9.38B | $8.37B | -17.5% |
| Total operating expense | $15.31B | $16.79B | $14.42B | $13.04B | -8.8% |
| Operating income | $8.34B | $5.54B | $7.34B | $6.73B | +50.5% |
| Net interest income | -$633.00M | -$603.00M | -$735.00M | -$826.00M | -5.0% |
| Pre-tax income | $7.40B | $3.48B | $6.06B | $5.63B | +112.9% |
| Tax provision | $1.11B | $526.00M | $756.00M | $707.00M | +111.4% |
| Net income | $5.72B | $2.58B | $4.93B | $14.96B | +122.0% |
| Net income to common | $5.72B | $2.58B | $4.93B | $14.96B | +122.0% |
| Basic EPS | 1.41 | 0.63 | 1.22 | 3.71 | +123.3% |
| Diluted EPS | 1.39 | 0.62 | 1.20 | 3.66 | +123.2% |
| EBIT | $8.09B | $4.12B | $6.79B | $6.45B | +96.5% |
| EBITDA | $10.40B | $6.67B | $9.08B | $8.60B | +56.0% |
| Basic shares | 4.05B | 4.08B | 4.05B | 4.03B | -0.6% |
| Diluted shares | 4.12B | 4.14B | 4.11B | 4.08B | -0.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $3.15B | $3.69B | $2.75B | $3.52B | -14.7% |
| Cash & short-term investments | $3.16B | $3.71B | $4.99B | $7.68B | -14.9% |
| Accounts receivable | $5.91B | $5.56B | $5.91B | $5.45B | +6.3% |
| Inventory | $5.92B | $5.67B | $5.50B | $5.15B | +4.5% |
| Total current assets | $17.51B | $17.00B | $18.64B | $20.77B | +3.0% |
| Property, plant & equipment | $10.05B | $10.07B | $9.96B | $9.62B | -0.2% |
| Goodwill & intangibles | $23.77B | $22.50B | $21.58B | $21.36B | +5.6% |
| Total assets | $61.12B | $59.46B | $59.01B | $60.15B | +2.8% |
| Total current liabilities | $21.39B | $21.70B | $21.07B | $22.81B | -1.4% |
| Current debt | $2.88B | $2.18B | $2.66B | $3.79B | +31.8% |
| Long-term debt | $14.02B | $13.70B | $14.15B | $16.19B | +2.3% |
| Total debt | $17.72B | $16.99B | $18.02B | $20.99B | +4.3% |
| Total liabilities | $45.16B | $46.38B | $46.21B | $50.05B | -2.6% |
| Retained earnings | $10.21B | $7.80B | $7.24B | $4.36B | +31.0% |
| Shareholder equity | $16.38B | $13.67B | $13.35B | $10.60B | +19.8% |
| Working capital | -$3.88B | -$4.70B | -$2.42B | -$2.04B | +17.4% |
| Net tangible assets | -$7.39B | -$8.83B | -$8.23B | -$10.77B | +16.3% |
| Shares issued | 4.32B | 4.31B | 4.31B | 4.31B | +0.0% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $6.29B | $2.95B | $5.31B | $4.92B | +113.1% |
| Depreciation & amortisation | $2.31B | $2.55B | $2.29B | $2.15B | -9.3% |
| Stock-based compensation | $374.00M | $344.00M | $307.00M | $346.00M | +8.7% |
| Change in working capital | -$1.44B | $2.09B | -$364.00M | $270.00M | -168.8% |
| Operating cash flow | $7.74B | $6.55B | $6.77B | $7.40B | +18.1% |
| Capital expenditure | -$2.98B | -$2.98B | -$2.34B | -$2.26B | -0.1% |
| Investing cash flow | -$4.23B | -$1.23B | -$1.59B | -$8.77B | -244.4% |
| Share buybacks | -$1.38B | $0 | $0 | — | — |
| Dividends paid | -$2.56B | -$2.44B | -$2.25B | -$3.47B | -4.9% |
| Financing cash flow | -$3.69B | -$4.73B | -$5.64B | $823.00M | +22.0% |
| Free cash flow | $4.76B | $3.57B | $4.42B | $5.14B | +33.1% |
| End cash position | $3.21B | $3.40B | $2.86B | $3.42B | -5.8% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $8.41B | $7.63B | $8.62B | $8.55B | $7.99B | — | +10.2% |
| Operating revenue | $8.41B | $7.63B | $8.62B | $8.55B | $7.99B | — | +10.2% |
| Cost of revenue | $2.27B | $1.88B | $2.66B | $2.26B | $2.17B | — | +20.9% |
| Gross profit | $6.14B | $5.75B | $5.96B | $6.29B | $5.82B | — | +6.8% |
| Research & development | $3.47B | $1.69B | $2.35B | $1.69B | $2.02B | — | +104.8% |
| Selling, general & admin | $2.20B | $2.12B | $2.64B | $2.24B | $2.14B | — | +3.9% |
| Total operating expense | $5.66B | $3.46B | $4.46B | $3.70B | $3.80B | — | +63.6% |
| Operating income | $481.00M | $2.29B | $1.51B | $2.59B | $2.02B | — | -79.0% |
| Net interest income | -$124.00M | -$145.00M | -$250.00M | -$141.00M | -$134.00M | — | +14.5% |
| Pre-tax income | $354.00M | $2.14B | $950.00M | $2.46B | $1.89B | — | -83.5% |
| Tax provision | -$199.00M | $305.00M | $223.00M | $312.00M | $241.00M | — | -165.2% |
| Net income | $435.00M | $1.74B | $636.00M | $2.01B | $1.44B | — | -75.0% |
| Net income to common | $435.00M | $1.74B | $636.00M | $2.01B | $1.44B | — | -75.0% |
| Basic EPS | 0.11 | 0.43 | 0.16 | — | 0.36 | 0.40 | -75.0% |
| Diluted EPS | 0.11 | 0.43 | 0.16 | — | 0.35 | 0.39 | -74.9% |
| EBIT | $536.00M | $2.31B | $1.12B | $2.62B | $2.07B | — | -76.8% |
| EBITDA | $2.83B | $2.77B | $1.12B | $3.36B | $3.23B | — | +1.9% |
| Basic shares | 4.01B | 4.02B | 4.02B | — | 4.06B | 4.09B | -0.2% |
| Diluted shares | 4.06B | 4.07B | 4.09B | — | 4.11B | 4.14B | -0.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Cash & equivalents | $3.10B | $3.44B | $3.15B | $3.30B | $3.60B | — | -9.8% |
| Cash & short-term investments | $3.11B | $3.44B | $3.16B | $3.31B | $3.62B | — | -9.8% |
| Accounts receivable | $7.71B | $7.76B | $5.91B | $7.94B | $7.32B | — | -0.6% |
| Inventory | $6.28B | $6.16B | $5.92B | $6.12B | $6.07B | — | +2.0% |
| Total current assets | $17.56B | $17.76B | $17.51B | $17.84B | $17.67B | — | -1.1% |
| Property, plant & equipment | $10.03B | $10.04B | $10.05B | $10.13B | $9.92B | — | -0.1% |
| Goodwill & intangibles | $24.18B | $25.43B | $23.77B | $23.98B | $22.11B | — | -4.9% |
| Total assets | $61.74B | $62.87B | $61.12B | $61.34B | $59.26B | — | -1.8% |
| Total current liabilities | $21.53B | $22.43B | $21.39B | $21.33B | $20.38B | — | -4.0% |
| Current debt | — | — | $2.88B | — | — | $2.18B | — |
| Long-term debt | — | — | $14.02B | — | — | $13.70B | — |
| Total debt | $18.24B | $19.06B | $17.72B | $17.75B | $17.35B | — | -4.3% |
| Total liabilities | $44.56B | $45.45B | $45.16B | $45.59B | $44.90B | — | -1.9% |
| Retained earnings | $11.46B | $11.59B | $10.21B | $10.02B | $8.80B | — | -1.1% |
| Shareholder equity | $17.64B | $17.85B | $16.38B | $16.15B | $14.79B | — | -1.2% |
| Working capital | -$3.98B | -$4.67B | -$3.88B | -$3.49B | -$2.71B | — | +14.8% |
| Net tangible assets | -$6.54B | -$7.57B | -$7.39B | -$7.83B | -$7.32B | — | +13.7% |
| Shares issued | 4.32B | 4.32B | 4.32B | 4.32B | 4.32B | — | +0.0% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | $553.00M | $1.84B | $727.00M | $2.14B | $1.65B | -69.9% |
| Depreciation & amortisation | $2.29B | $463.00M | -$406.00M | $738.00M | $1.16B | +394.6% |
| Change in working capital | $560.00M | -$1.08B | $588.00M | -$206.00M | -$1.03B | +151.8% |
| Operating cash flow | $2.69B | $1.14B | $2.28B | $2.22B | $2.10B | +135.8% |
| Capital expenditure | -$653.00M | -$443.00M | -$1.02B | -$879.00M | -$633.00M | -47.4% |
| Investing cash flow | -$789.00M | -$1.47B | -$933.00M | -$1.53B | -$625.00M | +46.2% |
| Share buybacks | -$308.00M | -$326.00M | -$252.00M | -$317.00M | -$561.00M | +5.5% |
| Dividends paid | -$727.00M | -$643.00M | -$646.00M | -$650.00M | -$656.00M | -13.1% |
| Financing cash flow | -$2.15B | $272.00M | -$856.00M | -$1.31B | -$2.37B | -890.1% |
| Free cash flow | $2.04B | $698.00M | $1.25B | $1.34B | $1.46B | +191.8% |
| End cash position | $2.94B | $3.20B | $3.21B | $2.76B | $3.32B | -8.0% |
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $8.90B | +4.1% |
| Next quarter | — | — | $8.99B | +4.3% |
| Current year | — | — | $33.94B | +3.9% |
| Next year | — | — | $35.54B | +4.7% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders1.75%
Held by institutions48.18%
Institutions holding716
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
25.47
+0.14% from price
SMA 20
25.59
-0.34% from price
SMA 50
25.75
-0.99% from price
SMA 100
26.10
-2.31% from price
SMA 200
25.82
-1.25% from price
EMA 12
25.47
+0.11% from price
EMA 26
25.57
-0.27% from price
EMA 50
25.69
-0.74% from price
RSI (14)
48.9
Neutral
MACD (12,26,9)
-0.10
Hist -0.01
ATR (14)
0.39
1.53% of price
Realised vol 30D
29.9%
Annualised
Bollinger upper
26.52
20, 2σ
Bollinger lower
24.65
20, 2σ
50 / 200 cross
Death
25.75 vs 25.82
Trend bias
Below 200
-1.25%
Risk profile
Beta vs SPY
-0.14
Less volatile than market
Correlation to SPY
-0.04
Largely independent
Realised vol 30D
29.9%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-24.0%
Peak to trough
Max drawdown 5Y
-53.1%
Peak to trough
ATR 14
0.39
1.53% of price
Beta (reported)
0.30
5Y monthly, from filing
Dividends & splits
Forward rate$0.92 / yr
Forward yield3.60%
5-year avg yield4.34%
Payout ratio56.88%
Ex-dividend dateAug 13, 2026
Next pay dateOct 10, 2019
Last split—
Split date—
Headlines
GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth
Proactive · 2d ago
Is Gilead's Expanding HIV Portfolio a Growth Catalyst?
Zacks · 4d ago
Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?
Insider Monkey · 9d ago
Wave Life Sciences: A $1 Billion RNA-Medicine Bargain Ripe for Pharma Takeover
24/7 Wall St. · 9d ago
Trump Plans to Sign Order on Splitting Up Combined Measles Shot
Bloomberg · 12d ago
Global Influenza Vaccine Market Report, 2026 Edition - Profiles GlaxoSmithKline, Pfizer, Sanofi, Moderna, and 9 Other Players
GlobeNewswire · 16d ago
GILD Q2 Earnings Beat on HIV and Trodelvy Growth, Product Sales Outlook Raised
Zacks · 17d ago
ViiV Healthcare Launches "Do It For Future You" Campaign Inspiring People to Prioritize Their Sexual Health and Future
Business Wire · 18d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.